[The results of a celiprolol drug surveillance study in Spain. The Celiprolol Multicenter Group].
The aim of this prospective multicenter study is to determine the efficacy and tolerance of a new, highly cardioselective beta-blocking agent with vasodilatation effects, Celiprolol. 185 patients with mild-light blood hypertension, grade 1-2, were admitted. Patient's progress was followed in 21 centers, 15 of them not being evaluated due to study protocol transgression. 82 patients were male and 87 female, with a median age of 50 +/- 11 (18-74). A doses of 200 mq/day of Celiprolol, once a day, during 2 weeks produced a significant statistical decrease of TAS and TAD (165 +/- 18 vs 151 +/- 18 mmHg, P less than 0.01 and 103.9 +/- 7 vs 94 +/- 9, P less than 0.01), with a minimal reduction of CR (78.5 +/- 10 vs 72.9 +/- 8 p min); 72 patients (43%) did not show a decrease in TAD lower than 95 mmHg, this being the reason to increase the celiprolol doses to 400 mg once a day, obtaining a decrease of TAS and TAD (TAS 146 +/- 16, P less than and TAD 90.5 +/- 9, P less than 0.01) with final CR of 71 +/- 8 p min. 18 patients had secondary effects, being mild in 16 cases, moderate in 2 and only one left the study spontaneously. 107 patients obtained a good control of blood hypertension (TAD less than 90) (62.9%), 80 of them with 200 mg doses. Analysing quality of life, 97 patients recognised that they left better (59.9%), 58 (35.8%) no different, and only 7 (4.3%) worse.(ABSTRACT TRUNCATED AT 250 WORDS)